These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38752574)

  • 41. Development of a hybrid physiologically based pharmacokinetic model with drug-specific scaling factors in rat to improve prediction of human pharmacokinetics.
    Sayama H; Komura H; Kogayu M; Iwaki M
    J Pharm Sci; 2013 Nov; 102(11):4193-204. PubMed ID: 24018828
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Predicting human pharmacokinetics from preclinical data.
    Poggesi I
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):100-11. PubMed ID: 14982153
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Artificial intelligence for compound pharmacokinetics prediction.
    Obrezanova O
    Curr Opin Struct Biol; 2023 Apr; 79():102546. PubMed ID: 36804676
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Novel In Vitro Method to Calculate Tissue-to-Plasma Partition Coefficient in Humans for Predicting Pharmacokinetic Profiles by Physiologically-Based Pharmacokinetic Model With High Predictability.
    Mayumi K; Tachibana M; Yoshida M; Ohnishi S; Kanazu T; Hasegawa H
    J Pharm Sci; 2020 Jul; 109(7):2345-2355. PubMed ID: 32283068
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challenges.
    Masimirembwa CM; Bredberg U; Andersson TB
    Clin Pharmacokinet; 2003; 42(6):515-28. PubMed ID: 12793837
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparing the applications of machine learning, PBPK, and population pharmacokinetic models in pharmacokinetic drug-drug interaction prediction.
    Gill J; Moullet M; Martinsson A; Miljković F; Williamson B; Arends RH; Pilla Reddy V
    CPT Pharmacometrics Syst Pharmacol; 2022 Dec; 11(12):1560-1568. PubMed ID: 36176050
    [TBL] [Abstract][Full Text] [Related]  

  • 47. IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with improved data and modelling strategies.
    Ahmad A; Pepin X; Aarons L; Wang Y; Darwich AS; Wood JM; Tannergren C; Karlsson E; Patterson C; Thörn H; Ruston L; Mattinson A; Carlert S; Berg S; Murphy D; Engman H; Laru J; Barker R; Flanagan T; Abrahamsson B; Budhdeo S; Franek F; Moir A; Hanisch G; Pathak SM; Turner D; Jamei M; Brown J; Good D; Vaidhyanathan S; Jackson C; Nicolas O; Beilles S; Nguefack JF; Louit G; Henrion L; Ollier C; Boulu L; Xu C; Heimbach T; Ren X; Lin W; Nguyen-Trung AT; Zhang J; He H; Wu F; Bolger MB; Mullin JM; van Osdol B; Szeto K; Korjamo T; Pappinen S; Tuunainen J; Zhu W; Xia B; Daublain P; Wong S; Varma MVS; Modi S; Schäfer KJ; Schmid K; Lloyd R; Patel A; Tistaert C; Bevernage J; Nguyen MA; Lindley D; Carr R; Rostami-Hodjegan A
    Eur J Pharm Biopharm; 2020 Nov; 156():50-63. PubMed ID: 32805361
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of Generic Methods to Predict Human Pharmacokinetics Using Physiologically Based Pharmacokinetic Model for Early Drug Discovery of Tyrosine Kinase Inhibitors.
    Ren HC; Sai Y; Chen T
    Eur J Drug Metab Pharmacokinet; 2019 Feb; 44(1):121-132. PubMed ID: 30039459
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The role of permeability in drug ADME/PK, interactions and toxicity--presentation of a permeability-based classification system (PCS) for prediction of ADME/PK in humans.
    Fagerholm U
    Pharm Res; 2008 Mar; 25(3):625-38. PubMed ID: 17710514
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection.
    Theil FP; Guentert TW; Haddad S; Poulin P
    Toxicol Lett; 2003 Feb; 138(1-2):29-49. PubMed ID: 12559691
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Drug Design and Success of Prospective Mouse In Vitro-In Vivo Extrapolation (IVIVE) for Predictions of Plasma Clearance (CL
    Manevski N; Umehara K; Parrott N
    Mol Pharm; 2023 Jul; 20(7):3438-3459. PubMed ID: 37235687
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The application of in silico drug-likeness predictions in pharmaceutical research.
    Tian S; Wang J; Li Y; Li D; Xu L; Hou T
    Adv Drug Deliv Rev; 2015 Jun; 86():2-10. PubMed ID: 25666163
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Recent progresses in the exploration of machine learning methods as in-silico ADME prediction tools.
    Tao L; Zhang P; Qin C; Chen SY; Zhang C; Chen Z; Zhu F; Yang SY; Wei YQ; Chen YZ
    Adv Drug Deliv Rev; 2015 Jun; 86():83-100. PubMed ID: 26037068
    [TBL] [Abstract][Full Text] [Related]  

  • 54. DallphinAtoM: Physiologically based pharmacokinetics software predicting human PK parameters based on physicochemical properties, in vitro and animal in vivo data.
    Choi S; Han S; Lee SJ; Lim B; Bae SH; Han S; Yim DS
    Comput Methods Programs Biomed; 2022 Apr; 216():106662. PubMed ID: 35151112
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prediction of Oral Pharmacokinetics Using a Combination of In Silico Descriptors and In Vitro ADME Properties.
    Kosugi Y; Hosea N
    Mol Pharm; 2021 Mar; 18(3):1071-1079. PubMed ID: 33512165
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetics in Drug Discovery: An Exposure-Centred Approach to Optimising and Predicting Drug Efficacy and Safety.
    Reichel A; Lienau P
    Handb Exp Pharmacol; 2016; 232():235-60. PubMed ID: 26330260
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Predicting Elimination of Small-Molecule Drug Half-Life in Pharmacokinetics Using Ensemble and Consensus Machine Learning Methods.
    Fan J; Shi S; Xiang H; Fu L; Duan Y; Cao D; Lu H
    J Chem Inf Model; 2024 Apr; 64(8):3080-3092. PubMed ID: 38563433
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prediction of Fraction Unbound in Microsomal and Hepatocyte Incubations: A Comparison of Methods across Industry Datasets.
    Winiwarter S; Chang G; Desai P; Menzel K; Faller B; Arimoto R; Keefer C; Broccatell F
    Mol Pharm; 2019 Sep; 16(9):4077-4085. PubMed ID: 31348668
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of an integrated in vitro-in silico PBPK (physiologically based pharmacokinetic) model to provide estimates of human bioavailability.
    Cai H; Stoner C; Reddy A; Freiwald S; Smith D; Winters R; Stankovic C; Surendran N
    Int J Pharm; 2006 Feb; 308(1-2):133-9. PubMed ID: 16352407
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PK/DB: database for pharmacokinetic properties and predictive in silico ADME models.
    Moda TL; Torres LG; Carrara AE; Andricopulo AD
    Bioinformatics; 2008 Oct; 24(19):2270-1. PubMed ID: 18684738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.